Does anyone know, if global pharmaceutical/biotech companies/NIH, USA/USFDA, NGOs, etc. will be willing to give/sell us small amounts (mg quantity) of their small molecule compounds (NCEs), where possible toxicity issues hampered their clinical development as cancer therapeutics? We are interested in further exploring Toxicogenomics and mechanism-of-actions of these NCEs in a mouse model of breast cancer? Even NCEs which failed in clinical development against other cancers will be of great research interest to us.
A further note of clarification-we will use these NCEs in Toxicogenomics studies in Ex Vivo breast tumor samples from mouse model and on isolated breast cancer stem cells. Any Intellectual property generated will be shared with the original innovator and CDA will be signed, if desired.
You can look at ZINC database.
zinc.docking.org
There are multiple vendors available for each compound. You can also try contact pharmaceutical companies for these. It sometimes work but their response is not sure.
This link may be useful to you
http://www.medicalnewstoday.com/releases/286656.php
Please check this URL from AstraZeneca
http://openinnovation.astrazeneca.com/what-we-offer/pharmacology-toolbox/?utm_source=LinkedIn&utm_medium=SponsoredUpdate&utm_campaign=OpenInnovation3
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology